Comparing different doses of magnesium for treating rapid atrial fibrillation

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial is a prospective, randomized, double-blinded study aimed at evaluating the safety and efficacy of intravenous magnesium at two different doses (2g and 4g) compared to a placebo in patients experiencing atrial fibrillation or atrial flutter with rapid ventricular response (AFF RVR). The study seeks to determine the optimal dosing of magnesium, which has been used as an adjunct therapy in managing cardiac arrhythmias. Participants will be monitored for their heart rates and overall response to the treatment, contributing to a better understanding of magnesium's role in this context.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age \> 18 years or older
* Able to provide informed consent
* Primary diagnosis AFF RVR greater than or equal to 120 bpm
* Diltiazem as rate control agent
* English speaking

Exclusion Criteria:

* Hemodynamically unstable patients (SBP \<90, MAP \<65)
* Impaired consciousness
* End stage renal disease on hemodialysis or peritoneal dialysis
* Acute heart failure exacerbation based on clinical diagnosis, physician exam, bedside echo, and/or additional imaging
* Patient in AFF RVR that is highly suspected to be a compensatory mechanism for an alternative clinical diagnosis
* Rhythms other than AF, such as sick sinus syndrome or wide-complex ventricular response
* Acute myocardial infarction
* Pregnancy defined as a positive urine HCG (human chorionic gonadotropin)
* Contraindications to magnesium sulfate (including myasthenia gravis)
* Allergy or sensitivity to any study drugs
* Previously enrolled in this trial during a different patient encounter
* Withdrew from study

Where it's running

• Advocate Christ Medical Center Emergency Department (ACMC ED)
  Oak Lawn, Illinois, United States Recruiting

Study contacts

• Principal investigator: Travis Hase, MD — Wake Forest University Health Sciences
• Study coordinator: Marc McDowell, PharmD
• Email: marc.mcdowell@aah.org
• Phone: (708) 684-1078

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• AI-based tools to help diagnose, treat and predict stroke outcomes across multiple hospitals

  This study tests AI-powered tools on real-world stroke patients to see if they can improve pre-hospital triage, diagnosis, and outcome prediction while data stay securely within each hospital.

  Recruiting at 2 sites Hospital Universitari Vall d'Hebron Research Institute · Leuven and 6 other locations · NCT07924371

• Left-atrial Fibrosis in Persistent Atrial Fibrillation and Its Comorbidities

  This study tests how comorbid conditions like sleep apnea and primary aldosteronism relate to left-atrial fibrosis and AF recurrence in patients undergoing ablation.

  Recruiting University Hospital Augsburg · Augsburg, Bavaria · NCT07857044

• Dual Energy ablation with SmartTouch SF catheter in persistent atrial fibrillation

  This study tests a pulsed field and radiofrequency ablation system to treat persistent atrial fibrillation in adults who have not responded well to prior medications.

  Recruiting at 4 sites Biosense Webster, Inc. · Beijing and 3 other locations · NCT07845682

• Identifying AF patients who may need more than standard ablation using Volta AF-Xplorer II

  This trial tests whether AI-identified dispersion areas during AF ablation can predict recurrence after a standard pulmonary vein isolation in patients with persistent AF.

  Recruiting Volta Medical · Avignon and 4 other locations · NCT07807423

• 4D intracardiac echocardiography to guide left atrial appendage occlusion procedures

  A new 4D ICE catheter is being tested alongside standard imaging to see if it can safely guide left atrial appendage occlusion procedures for adults with atrial fibrillation.

  Recruiting The Cleveland Clinic · Cleveland, Ohio · NCT07806890

• Thoracoscopic vs Catheter Ablation as the First Rhythm Control in Atrial Fibrillation with a Large Left Atrium

  This trial tests whether thoracoscopic surgical ablation is better at keeping atrial fibrillation under control than catheter ablation in people with persistent AF and a large left atrium who have not had an ablation before.

  Recruiting Samsung Medical Center · Seoul, Seoul · NCT07783984

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.